TG Therapeutics (NasdaqCM:TGTX) FY Conference Transcript

TG Therapeutics Conference Call Summary Company Overview - Company: TG Therapeutics (NasdaqCM:TGTX) - Focus: B-cell mediated diseases, primarily multiple sclerosis (MS) - Approved Drug: Briumvi, an anti-CD20 monoclonal antibody for MS, launched in January 2023 - Market Presence: Available in 16 countries, with over 20,000 patients prescribed Briumvi to date [2][3] Core Market Insights - Anti-CD20 Market: Represents approximately $10 billion in sales, with Briumvi capturing about 20% of the total market share and one-third of the healthcare provider-administered segment [4][6] - Growth Potential: The anti-CD20 class holds a 50% market share in new prescriptions, indicating room for growth [4][5] Financial Performance - 2026 Revenue: Total global revenues of $616 million, with U.S. net revenue of $594 million, reflecting a 90% year-over-year growth [7][9] - Cumulative Revenue: Exceeded $1 billion in cumulative net sales within less than three years of launch [6][7] - Forecast for 2026: Targeting $875 million to $900 million in global net revenue, primarily from U.S. sales [27][28] Product Development and Future Plans - Upcoming Trials: - Enhanced IV protocol aimed at consolidating dosing to simplify onboarding, with top-line data expected mid-2026 [18][19] - Development of a self-administered subcutaneous (subcu) version of Briumvi, with a pivotal study currently over 50% enrolled and a target launch in 2028 [20][21] - Expansion Beyond MS: Plans to explore additional indications for Briumvi, including myasthenia gravis (MG) and neuromyelitis optica (NMO) [25][26] Competitive Landscape - Market Positioning: Briumvi is positioned as the lowest-priced branded MS treatment, enhancing its appeal in a competitive market [12][13] - Sales Force Strategy: Plans to increase the sales force by 10%-20% to target high-opportunity healthcare providers [14][34] R&D and Pipeline - Azer-cel: An allogeneic off-the-shelf CD19 CAR-T product in development for progressive MS, with data expected in 2026 [25][44] - Long-term Opportunities: Patents extending into the mid-2040s, with ongoing evaluations for new indications and potential drug launches [31] Key Takeaways - Market Dynamics: Briumvi's growth trajectory is strong, with significant market share gains and a robust pipeline for future growth [30][31] - Operational Efficiency: The company maintains low operating expenses relative to revenue, indicating potential for profitability acceleration [31][29] - Patient Engagement: Emphasis on patient awareness campaigns to drive market share, recognizing the importance of shared decision-making in MS treatment [15][16] Conclusion - TG Therapeutics is well-positioned for continued growth in the MS market with Briumvi, supported by strategic product development and a focus on patient and healthcare provider engagement. The company anticipates significant revenue growth and operational efficiency in the coming years, with a strong pipeline of future products and indications.